Two-step computational validation approach to ascertain the inferential validity of the proposed GBA. 4A shows the ratio of the average Boolean score given to cancer genes over the average score given to the other genes. Candidate genes comprising the top 13.2% of genes guarantee a 2.71-fold over-representation of cancer genes. 4B. Standard cross-validation in which the proportion of cancer-associated genes are compared to genes with extreme Boolean scores. By selecting the 50% most extreme genes captures 90% of all cancer genes.